Clinical efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors in treatment of metastatic renal cancer

Wang Jiyuan; Tong Hang; Kuang Youlin; Yin Hubin; He Weiyang

doi:10.13406/j.cnki.cyxb.004043

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors in treatment of metastatic renal cancer

Precision medicine in cancer and translational studies | 更新时间：2026-05-13

- Clinical efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors in treatment of metastatic renal cancer
- Journal of Chongqing Medical University Vol. 51, Issue 5, Pages: 632-637(2026)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.004043
  CLC： R737.11
- Received：02 December 2025，
  
  Revised：2026-01-11，
  
  Accepted：20 January 2026，
  
  Published：28 May 2026
- 稿件说明：
移动端阅览
王纪元，童行，匡幼林，等.替雷利珠单抗联合酪氨酸激酶抑制剂治疗转移性肾癌的临床疗效及安全性分析[J].重庆医科大学学报，2026，51（5）：632-637.

Wang Jiyuan,Tong Hang,Kuang Youlin,et al.Clinical efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors in treatment of metastatic renal cancer[J].Journal of Chongqing Medical University,2026,51(5):632-637.
王纪元，童行，匡幼林，等.替雷利珠单抗联合酪氨酸激酶抑制剂治疗转移性肾癌的临床疗效及安全性分析[J].重庆医科大学学报，2026，51（5）：632-637. DOI： 10.13406/j.cnki.cyxb.004043.

Wang Jiyuan,Tong Hang,Kuang Youlin,et al.Clinical efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors in treatment of metastatic renal cancer[J].Journal of Chongqing Medical University,2026,51(5):632-637. DOI： 10.13406/j.cnki.cyxb.004043.

摘要

目的

探讨替雷利珠单抗联合靶向药物酪氨酸激酶抑制剂治疗转移性肾癌患者的临床疗效及安全性。

方法

回顾性分析2020年4月至2025年3月在重庆医科大学附属第一医院泌尿外科分别接受替雷利珠单抗联合靶向药物酪氨酸激酶抑制剂治疗的40例晚期肾癌患者，以及39例靶向药物单药治疗的晚期肾癌患者的相关临床资料。单靶治疗组为只接受酪氨酸激酶抑制剂（如舒尼替尼、培唑帕尼、阿昔替尼或仑伐替尼等）的肾癌患者。联合治疗组为靶向药物联合替雷利珠单抗（百泽安）治疗的患者。比较2组患者的临床疗效、生存时间、无进展生存期、肿瘤特异性生存期及不良反应等。

结果

联合治疗组与单靶治疗组在客观缓解率和疾病控制率方面差异有统计学意义。联合治疗组的中位总生存期为42.00个月，单靶治疗组为29.00个月，差异无统计学意义（

=0.354）。联合治疗组的中位无进展生存期为10.50个月，单靶治疗组为9.00个月，差异有统计学意义（

=0.008）。2组患者常见不良反应包括皮肤及附件损害、食欲减退、乏力、白细胞减少等。联合治疗组1~2级和3~4级不良反应发生率为72.5%、20.0%，单靶治疗组1~2级和3~4级不良反应发生率为74.4%、23.1%，单靶治疗组发生率略高，但差异均无统计学意义（

0.05）。

结论

联合治疗组相较于单靶治疗组在晚期肾癌中展现了更好的临床疗效，尤其是无进展生存期获益。不良反应发生率虽高，总体在耐受范围之内，安全性可控。

Abstract

Objective

To investigate the clinical efficacy and safety of tislelizumab combined with tyrosine kinase inhibitors（TKIs） in the treatment of patients with metastatic renal cancer.

Methods

A retrospective analysis was performed for the clinical data of 40 patients with advanced renal cancer who received tislelizumab combined with TKIs and 39 patients with advanced renal cancer who received monotherapy with TKIs in Department of Urology，The First Affiliated Hospital of Chongqing Medical University，from April 2020 to March 2025. The patients in the monotherapy group were renal cancer patients treated with TKIs（such as sunitinib，pazopanib，axitinib，and lenvatinib） alone，while those in the combination therapy group were the patients treated with TKIs combined with tislelizumab（Tevimbra）. The two groups were compared in terms of clinical outcome，survival time，progression-free survival，cancer-specific survival，and adverse reactions.

Results

There were significant differences in objective response rate and disease control rate between the combination therapy group and the monotherapy group. There was no significant difference in median overall survival between the combination therapy group and the monotherapy group（42.00 months vs. 29.00 months，

=0.354），while there was a significant difference in median progression-free survival between the two groups （10.50 months vs. 9.00 months，

=0.008）. Common adverse reactions in the two groups included rash，anorexia，fatigue，and leukopenia. For the combination therapy group，the incidence rates of grade 1-2 or 3-4 adverse reactions were 72.5% and 20.0%，respectively，while for the monotherapy group，the incidence rates of grade 1-2 or 3-4 adverse reactions were 74.4% and 23.1%，respectively； the monot

herapy group had slightly higher incidence rates than the combination therapy group，with no significant differences between the two groups（

0.05）.

Conclusion

Combination therapy has a better clinical efficacy than monotherapy in advanced renal cancer，particularly in terms of progression-free survival. Although there is a relatively high incidence rate of adverse reactions，it remains generally tolerable with a controllable safety profile.

关键词

Keywords

references

马培菊，龙庭凤，左相曾，等 . MiR-103a-3p 在恶性肿瘤中的作用及机制研究进展 [J ] . 肿瘤预防与治疗， 2024 ， 37 （ 1 ）： 68 - 75 ．

Ma PJ ， Long TF ， Zuo XZ ， et al . Research progress on the role and mechanism of MiR-103a-3p in malignant tumors [J ] . J Cancer Prev Treat ， 2024 ， 37 （ 1 ）： 68 - 75 ．

曾永毅，林孔英，陈清静 . 肝细胞癌转化和新辅助治疗的进展与挑战 [J ] . 中华消化外科杂志， 2023 ， 22 （ 2 ）： 195 - 201 ．

Zeng YY ， Lin KY ， Chen QJ . Advances and challenges of conversion therapy and neoadjuvant therapy in hepatocellular carcinoma [J ] . Chin J Dig Surg ， 2023 ， 22 （ 2 ）： 195 - 201 ．

Schwartz LH ， Litière S ， de Vries E ， et al . RECIST 1.1-Update and clarification： From the RECIST committee [J ] . Eur J Cancer ， 2016 ， 62 ： 132 - 137 ．

周硕明，甘卫东 . 2022版欧洲泌尿外科学会肾细胞癌诊疗指南更新要点解读 [J/OL ] . 中华腔镜泌尿外科杂志（电子版）， 2023 ， 17 （ 2 ）： 100 - 104 ．

Zhou SM ， Gan WD . Interpretation of the updated key points of the European Society of Urology’s guidelines for the diagnosis and treatment of renal cell carcinoma （ 2022 ）[J/OL ] . Chin J Endourol Electron Ed ， 2023 ， 17 （ 2 ）： 100 - 104 ．

Liu ZL ， Chen HH ， Zheng LL ， et al . Angiogenic signaling pathways and anti-angiogenic therapy for cancer [J ] . Signal Transduct Target Ther ， 2023 ， 8 （ 1 ）： 198 ．

Jin J ， Xie YH ， Zhang JS ， et al . Sunitinib resistance in renal cell carcinoma：From molecular mechanisms to predictive biomarkers [J ] . Drug Resist Updat ， 2023 ， 67 ： 100929 ．

Simonaggio A ， Epaillard N ， Pobel C ， et al . Tumor microenvironment features as predictive biomarkers of response to immune checkpoint inhibitors（ICI） in metastatic clear cell renal cell carcinoma （mccRCC） [J ] . Cancers ， 2021 ， 13 （ 2 ）： 231 ．

Hughes PE ， Caenepeel S ， Wu LC . Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer [J ] . Trends Immunol ， 2016 ， 37 （ 7 ）： 462 - 476 ．

Powles T ， Plimack ER ， Soulières D ， et al . Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma（KEYNOTE-426）：extended follow-up from a randomised，open-label，phase 3 trial [J ] . Lancet Oncol ， 2020 ， 21 （ 12 ）： 1563 - 1573 ．

Gu LY ， Peng C ， Li HK ， et al . Neoadjuvant therapy in renal cell carcinoma with tumor thrombus：A systematic review and meta-analysis [J ] . Crit Rev Oncol Hematol ， 2024 ， 196 ： 104316 ．

Huang JW ， Wang YM ， Xu F ， et al . Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma：a single-arm，phase II trial [J ] . J Immunother Cancer ， 2024 ， 12 （ 6 ）： e008475 ．

姚欣，周芳坚，李长岭，等 . 晚期肾透明细胞癌系统性治疗中国专家共识（2024版） [J ] . 中华肿瘤杂志， 2024 ， 46 （ 9 ）： 844 - 854 .

Yao X ， Zhou FJ ， Li CL ， et al . Chinese expert consensus on the systemic treatment of advanced clear cell renal cell carcinoma（2024 edition） [J ] . Chin J ， 2024 ， 46 （ 9 ）： 844 - 854 .

Zheng XJ ， Gu HF ， Cao XP ， et al . Tislelizumab for cervical cancer：A retrospective study and analysis of correlative blood biomarkers [J ] . Front Immunol ， 2023 ， 14 ： 1113369 ．

Zhao ZJ ， Liu ZS ， Zhang KY ， et al . Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena Cava tumor thrombus：a retrospective study [J ] . Sci Rep ， 2025 ， 15 （ 1 ）： 2248 ．

Wen J ， Chang XC ， Bai BW ， et al . Orexin a suppresses the expression of exosomal PD-L1 in colon cancer and promotes T cell activity by inhibiting JAK2/STAT3 signaling pathway [J ] . Dig Dis Sci ， 2022 ， 67 （ 6 ）： 2173 - 2181 ．

蒋炳良，黄　超，刘正升，等 . 转移性肾癌基于免疫检查点抑制剂治疗的单中心经验总结 [J ] . 临床泌尿外科杂志， 2024 ， 39 （ 11 ）： 989 - 994 ．

Jiang BL ， Huang C ， Liu ZS ， et al . Summary of single-center experience in the treatment of metastatic renal cancer based on immune checkpoint inhibitors [J ] . J Clin Urol ， 2024 ， 39 （ 11 ）： 989 - 994 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Risk factors and prognosis of checkpoint inhibitor pneumonitis

Comparison of efficacy and complications of endoscopic surgery through three different approaches in the treatment of thyroid microcarcinoma

Advances in immunotherapy in EGFR-mutated non-small cell lung cancer

Efficacy of systemic anticoagulation combined with endovascular treatment for cerebral venous sinus thrombosis

Transcription factor SP1 regulates mouse embryonic development by targeting developmental genes

Related Author

Wang Jun

Xie Hong

Wang Yabing

Liu Sanbao

Ren Junling

Tang Hao

Wu Junfeng

Wei Kunchen

Related Institution

Department of Oncology， The First Affiliated Hospital of Shandong First Medical University

School of Clinical Medicine，Shandong Second Medical University

Department of Thyroid and Breast Surgery，The Second Affiliated Hospital of Wannan Medical College

Department of Thyroid and Breast Surgery，Yijishan Hospital，The First Affiliated Hospital of Wannan Medical College

Department of Respiratory and Critical Care Medicine,Shanghai Changzheng Hospital

⁰